BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 9227927)

  • 1. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group.
    Guilhot F; Chastang C; Michallet M; Guerci A; Harousseau JL; Maloisel F; Bouabdallah R; Guyotat D; Cheron N; Nicolini F; Abgrall JF; Tanzer J
    N Engl J Med; 1997 Jul; 337(4):223-9. PubMed ID: 9227927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
    Millot F; Guilhot J; Nelken B; Leblanc T; Leverger G; Bernard F; Gandemer V; Béhard C; Berger C; Cornu G; Duchène S; Guilhot F
    Pediatr Blood Cancer; 2006 Oct; 47(5):555-9. PubMed ID: 16317737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG; Guilhot F; Larson RA; Gathmann I; Baccarani M; Cervantes F; Cornelissen JJ; Fischer T; Hochhaus A; Hughes T; Lechner K; Nielsen JL; Rousselot P; Reiffers J; Saglio G; Shepherd J; Simonsson B; Gratwohl A; Goldman JM; Kantarjian H; Taylor K; Verhoef G; Bolton AE; Capdeville R; Druker BJ;
    N Engl J Med; 2003 Mar; 348(11):994-1004. PubMed ID: 12637609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Hematologic and cytogenetic response to treatment in patients with chronic myeloid leukemia].
    Tóthová E; Fricová M; Stecová N; Kafková A; Mudronová B; Svorcová E; Guman T; Raffac S; Hlebasková M
    Cas Lek Cesk; 2000 Jul; 139(14):437-9. PubMed ID: 11048406
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The 6M 12M trial--study of the effectivess and tolerance of treatment in chronic myeloid leukaemia with a combination of interferon alfa and cytarabine].
    Tóthová E; Fricová M; Stecová N; Svorcová E; Guman T; Rraffac S; Kafková A; Hlebasková M
    Vnitr Lek; 2000 Jul; 46(7):391-4. PubMed ID: 15635799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of the chronic phase of chronic myeloid leukemia with an intermittent schedule of recombinant interferon alfa-2b and cytarabine: results from CALGB study 9013.
    Silver RT; Peterson BL; Szatrowski TP; Powell BL; Stock W; Carroll AJ; Bloomfield CD; Schiffer CA; Larson RA
    Leuk Lymphoma; 2003 Jan; 44(1):39-48. PubMed ID: 12691141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined interferon alfa-2a and cytosine arabinoside as first-line treatment for chronic myeloid leukemia.
    Arthur CK; Ma DD
    Acta Haematol; 1993; 89 Suppl 1():15-21. PubMed ID: 8475667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea.
    Hehlmann R; Berger U; Pfirrmann M; Hochhaus A; Metzgeroth G; Maywald O; Hasford J; Reiter A; Hossfeld DK; Kolb HJ; Löffler H; Pralle H; Queisser W; Griesshammer M; Nerl C; Kuse R; Tobler A; Eimermacher H; Tichelli A; Aul C; Wilhelm M; Fischer JT; Perker M; Scheid C; Schenk M; Weiss J; Meier CR; Kremers S; Labedzki L; Schmeiser T; Lohrmann HP; Heimpel H;
    Leukemia; 2003 Aug; 17(8):1529-37. PubMed ID: 12886239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.
    Hensley ML; Peterson B; Silver RT; Larson RA; Schiffer CA; Szatrowski TP
    J Clin Oncol; 2000 Mar; 18(6):1301-8. PubMed ID: 10715301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.
    Preudhomme C; Guilhot J; Nicolini FE; Guerci-Bresler A; Rigal-Huguet F; Maloisel F; Coiteux V; Gardembas M; Berthou C; Vekhoff A; Rea D; Jourdan E; Allard C; Delmer A; Rousselot P; Legros L; Berger M; Corm S; Etienne G; Roche-Lestienne C; Eclache V; Mahon FX; Guilhot F; ;
    N Engl J Med; 2010 Dec; 363(26):2511-21. PubMed ID: 21175313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a phase II trial of a combination of oral cytarabine ocfosfate (YNK01) and interferon alpha-2b for the treatment of chronic myelogenous leukemia patients in chronic phase.
    Maloisel F; Guerci A; Guyotat D; Ifrah N; Michallet M; Reiffers J; Tertain G; Blanc M; Bauduer F; Brière J; Abgrall JF; Pegourie-Bandelier B; Solary E; Cambier N; Coso D; Vilque JP; Delain M; Harousseau JL; Rousselot P; Belhadj K; Morice P; Attal J; Chabin M; Chastang C; Guilhot J; Guilhot F;
    Leukemia; 2002 Apr; 16(4):573-80. PubMed ID: 11960335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study.
    Giles FJ; Shan J; Chen S; Advani SH; Supandiman I; Aziz Z; Caviles AP; Tee GY; Chasen MR; Fahed Z; Chaoj TY; Aydogdu I; Lynott AM
    Leuk Lymphoma; 2000 Apr; 37(3-4):367-77. PubMed ID: 10752988
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-interferon in combination with cytarabine in children with Philadelphia chromosome-positive chronic myeloid leukemia.
    Millot F; Brice P; Philippe N; Thyss A; Demeoq F; Wetterwald M; Boccara JF; Vilque JP; Guyotat D; Guilhot J; Guilhot F
    J Pediatr Hematol Oncol; 2002 Jan; 24(1):18-22. PubMed ID: 11902732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
    O'Brien S; Giles F; Talpaz M; Cortes J; Rios MB; Shan J; Thomas D; Andreeff M; Kornblau S; Faderl S; Garcia-Manero G; White K; Mallard S; Freireich E; Kantarjian HM
    Cancer; 2003 Sep; 98(5):888-93. PubMed ID: 12942553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    Druker BJ; Guilhot F; O'Brien SG; Gathmann I; Kantarjian H; Gattermann N; Deininger MW; Silver RT; Goldman JM; Stone RM; Cervantes F; Hochhaus A; Powell BL; Gabrilove JL; Rousselot P; Reiffers J; Cornelissen JJ; Hughes T; Agis H; Fischer T; Verhoef G; Shepherd J; Saglio G; Gratwohl A; Nielsen JL; Radich JP; Simonsson B; Taylor K; Baccarani M; So C; Letvak L; Larson RA;
    N Engl J Med; 2006 Dec; 355(23):2408-17. PubMed ID: 17151364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
    Beck JR; Guilhot J; Giles FJ; Aoki N; Wirt DP; Guilhot F
    Leuk Lymphoma; 2001 Mar; 41(1-2):117-24. PubMed ID: 11342363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced stages of Philadelphia chromosome-positive chronic myelogenous leukemia with interferon-alpha and low-dose cytarabine.
    Kantarjian HM; Keating MJ; Estey EH; O'Brien S; Pierce S; Beran M; Koller C; Feldman E; Talpaz M
    J Clin Oncol; 1992 May; 10(5):772-8. PubMed ID: 1569449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.